Drugs / VLP-Polio
VLP-Polio
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06101173 | Jan → Mar 2024 | poliomyelitis | CanSino Biologics Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06577298 | Dec 2024 → Oct 2026 expected | poliomyelitis | CanSino Biologics Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-07-16 | CanSino Biologics Inc. | Regulatory CanSinoBIO's Innovative Recombinant Poliomyelitis Vaccine Obtains Clinical Trial Approval in China cansinotech.com ↗
CanSino Biologics Inc. ("CanSinoBIO" or "the Company") has announced that it has obtained clinical trial approval from the National Medical Products Administration (NMPA) of China to initiate relevant clinical trials for its Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (the "Recombinant Poliomyelitis Vaccine"). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-07-16 | CanSino Biologics Inc. | CanSinoBIO's Innovative Recombinant Poliomyelitis Vaccine Obtains Clinical Trial Approval in China cansinotech.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VLP-Polio | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06577298 ↗ |
| Known as | Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) | “Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio)” NCT06101173 ↗ |
| Known as | Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) | “Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose” NCT06577298 ↗ |
| Modality | Vaccine | “Recombinant Trivalent Poliomyelitis Vaccine” NCT06101173 ↗ |
| Route | Intramuscular | “Intramuscular injection (IM)” NCT06101173 ↗ |